Published in Blood on June 15, 1993
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia (2013) 3.08
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc (2010) 1.34
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Variance Estimation in Censored Quantile Regression via Induced Smoothing. Comput Stat Data Anal (2010) 0.96
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia (2010) 0.94
Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia (2012) 0.91
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood (2015) 0.86
Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc (2010) 0.83
Induction of malignant plasma cell proliferation by eosinophils. PLoS One (2013) 0.82
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol (2015) 0.80
Clinical value of new staging systems for multiple myeloma. Cancer Res Treat (2007) 0.79
A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma. J Mol Diagn (2005) 0.79
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med (2013) 0.78
Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. J Clin Pathol (1995) 0.78
Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy. J Clin Pathol (1995) 0.78
Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant (2008) 0.77
Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma. J Korean Med Sci (2006) 0.77
Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis. Oncol Lett (2015) 0.77
The treatment of multiple myeloma--an important MRC trial. Br J Cancer (1994) 0.76
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood (2011) 0.75
Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. Cancer Med (2016) 0.75
Evaluation of argyrophilic nucleolar organiser regions (AgNORs) in multiple myeloma. J Clin Pathol (2000) 0.75
The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol (2017) 0.75
Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? Blood (1993) 0.75
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. J Cancer Res Clin Oncol (2016) 0.75
Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet (2003) 11.91
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Risk of connective-tissue diseases and other disorders after breast implantation. N Engl J Med (1994) 9.25
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 5.49
A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis (1992) 5.22
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Multiple myeloma: review of 869 cases. Mayo Clin Proc (1975) 4.59
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke (1996) 4.13
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med (1982) 3.77
Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Carpal tunnel syndrome in Rochester, Minnesota, 1961 to 1980. Neurology (1988) 3.40
Amyloidosis: review of 236 cases. Medicine (Baltimore) (1975) 3.39
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc (1983) 3.22
Perturbation of the T-cell repertoire in patients with unstable angina. Circulation (1999) 3.20
The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol (1980) 3.19
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med (1978) 3.08
Epidemiology of cervical radiculopathy. A population-based study from Rochester, Minnesota, 1976 through 1990. Brain (1994) 3.07
T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 3.06
Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum (1999) 2.98
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med (1999) 2.98
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum (1984) 2.85
Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int (1999) 2.83
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc (1999) 2.80
Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med (1986) 2.80
Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int (1979) 2.79
Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke (2000) 2.78
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol (2001) 2.78
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation (1999) 2.71
Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med (1978) 2.70
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol (2000) 2.68
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
Intercessory prayer and cardiovascular disease progression in a coronary care unit population: a randomized controlled trial. Mayo Clin Proc (2001) 2.61
Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med (1970) 2.61
Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol (1991) 2.59
Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res (1993) 2.59
Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke (1999) 2.56
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum (1999) 2.50
Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol (1996) 2.48
Long-term survival of a cohort of community residents with asthma. N Engl J Med (1994) 2.47
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis (2007) 2.46
Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab (2001) 2.43
Emotional responses of athletes to injury. Mayo Clin Proc (1990) 2.43
Accuracy of the death certificate in a population-based study of asthmatic patients. JAMA (1993) 2.42
Correlation of cerebral blood flow and electroencephalographic changes during carotid endarterectomy: with results of surgery and hemodynamics of cerebral ischemia. Mayo Clin Proc (1981) 2.41
Secular trends in the incidence of hip fractures. Calcif Tissue Int (1987) 2.40
Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res (1990) 2.39
50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry (1991) 2.38
Osteoporosis and the risk of hip fracture. Am J Epidemiol (1986) 2.35
Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis (2003) 2.34
Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol (1999) 2.34
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med (1995) 2.27
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med (1982) 2.24
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc (2001) 2.17
Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984) Neurology (1996) 2.16
Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13
Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med (1983) 2.13
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol (1999) 2.07
The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg (1988) 2.06
Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy. Pediatrics (1968) 2.06
Complications leading to surgery after breast implantation. N Engl J Med (1997) 2.05
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med (1995) 2.02
Serum lipids and lipoproteins are less powerful predictors of extracranial carotid artery atherosclerosis than are cigarette smoking and hypertension. Mayo Clin Proc (1991) 2.02
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol (2001) 2.00
Risk factors for spinal osteoporosis in men. Am J Med (1983) 2.00
Epidemiology of sarcopenia. J Am Geriatr Soc (2000) 1.97
Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab (2002) 1.96
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res (1998) 1.93
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology (1998) 1.92
The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol (1997) 1.91
Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol (1997) 1.91
Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol (1993) 1.91